CBL-514 injection + 0.9% Sodium chloride
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dercum's Disease
Conditions
Dercum's Disease
Trial Timeline
Nov 27, 2024 → Apr 1, 2026
NCT ID
NCT06303570About CBL-514 injection + 0.9% Sodium chloride
CBL-514 injection + 0.9% Sodium chloride is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Dercum's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06303570. Target conditions include Dercum's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06303570 | Phase 2 | Recruiting |
Competing Products
1 competing product in Dercum's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 10 mg CBL-514 per injection + 15 mg CBL-514 per injection | Caliway Biopharmaceuticals | Phase 2 | 51 |